Corcept Therapeutics Incorporated reported its financial results for the third quarter ended September 30, 2026, with revenue of $340.5 million, representing a 64 percent increase over the same period in 2025. This total included Korlym and authorized generic product revenue of $

Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 million

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IREN Ltd (Symbol: IREN), where a total volume of 351,428 contracts has been traded thus far today, a contract volume which is representative of approximately 35.

Notable Tuesday Option Activity: IREN, HTZ, CORT

CORCEPT THERAPEUTICS INC filed a 144

Here is how Aspen Pharmacare (APNHY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Rivian Automotive Inc (Symbol: RIVN), where a total volume of 107,237 contracts has been traded thus far today, a contract volume which is representative of appr

Notable Tuesday Option Activity: RIVN, CORT, AAOI

Insider reported a trade at CORCEPT THERAPEUTICS INC

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated News